Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2020.02.19

Dean Edney

Accomplished scientific leader and GSK veteran, Dean Edney joins Sai Life Sciences

Sai Life Sciences, today announced the appointment of Dr. Dean Edney as Senior Vice President and Global Head of Process Research & Development. An accomplished scientific leader and industry veteran with over 25 years of experience in small molecule pharmaceutical process and product development, Dean Edney will split his time between the company’s R&D centre in Hyderabad, India and the new R&D facility in Alderley Park, Manchester, UK.

Making the announcement, CEO & Managing Director of Sai Life Sciences, Krishna Kanumuri said, “We are delighted to welcome Dean on board Sai Life Sciences as we open our new Process R&D facility in Manchester, UK. His joining strengthens our vision of creating a world-class, global process R&D organization that applies cutting edge scientific approaches and technology to rapidly deliver high-quality scientific output irrespective of the geographical location.”

As part of its organization-wide transformation initiative, Sai Nxt, the company aspires to enhance its Process Research & Development (PR&D) capability allowing customers to accelerate their research and development programs and deliver commercial products through the rapid application of high quality science to all areas of API process research, development and manufacturing. It will achieve this by combining expertise in rapid, cost effective, process optimisation and scale-up in Hyderabad with expertise in application of new technology and parallel & statistical approaches to process development in Manchester into a single global PR&D organisation.

Commenting on his appointment, Dean Edney said, "I am incredibly excited to be joining Sai Life Sciences at a time of significant investment and growth. My aim is to ensure that the investment in facilities and technology is matched by investment in people and capability, thereby accelerating our clients’ ability to deliver new medicines to patients.”

Previously, over a 25-year career at GlaxoSmithKline, Dean demonstrated a strong track record of cross-functional leadership to deliver projects and develop capability across all phases of API process research & development, from early non-clinical supply and route scouting through to validation of commercial control strategies. Dean received his BSc in Chemistry and Ph.D. in Synthetic Organic Chemistry from the University of Nottingham, UK.

Share article

More News

2026.03.27

Inside Sai Life Sciences’ Integrated R&D Campus: Accelerating Drug Development

In a recent feature published in R&D World, Sai Life Sciences’ Integrated R&D Campus in Hyderabad is showcased as a model for accelerating drug discovery and development through true scientific integration.In the article, Dr. B.V.N.B.S. Sarma, Senior Vice President – Discovery, highlights how co-locating multidisciplinary teams—from medicinal chemistry and biology to DMPK, developability, process development, […]
Read more

2026.03.27

Sai Life Sciences hosts Biotech Pitch Day 2026 at Boston Site

Sai Life Sciences successfully hosted its Biotech Pitch Day 2026 at its Boston-area site on March 19, bringing together a dynamic group of emerging biotech innovators, scientific leaders, and industry experts. The event was designed as a platform for early-stage biotech companies to showcase their science, strengthen visibility, and engage with potential collaborators across the […]
Read more

2026.03.25

Kudikunta Lake restoration completed, marking the revival of an urban water body

Kudikunta Lake in Kondapur, Hyderabad, was inaugurated on February 28th following the completion of restoration efforts undertaken by Sai Life Sciences as part of its Corporate Social Responsibility (CSR) initiative in collaboration with the Society for Advancement of Human Endeavour (SAHE). The event marked the culmination of several months of work to restore a previously […]
Read more

2026.03.10

AI-driven retrosynthesis integrated into Discovery Chemistry

Sai Life Sciences has entered into a collaboration with Chemical.AI, a technology company specialising in computer-aided synthesis design, to integrate an AI-driven retrosynthesis platform into its Discovery Chemistry workflows. The integration enables medicinal chemists to evaluate synthetic routes more rapidly and explore a broader set of feasible pathways during early-stage drug discovery. Retrosynthesis is a […]
Read more

2026.03.10

Structural Biology capabilities launched with X-Ray Crystallography

Sai Life Sciences has introduced integrated structural biology capabilities with the establishment of X-ray protein crystallography workflows to support structure-based drug discovery programs. The platform encompasses end-to-end protein engineering capabilities, including construct design, gene synthesis, and in-house recombinant protein expression and purification. These foundational steps enable generation of high-quality protein material suitable for structural and […]
Read more